Overview / Abstract: |
Target Audience This activity is designed to meet the educational needs of medical oncologists, urologic oncologists, nurse practitioners, PAs, nurses and other healthcare professionals who manage patients with mCRPC. Program Overview A focused online module that examines the mechanistic rationale, discusses the latest evidence, and explores the potential role of PARP inhibitor-based combination therapy in the treatment of patients with advanced prostate cancer. Learning Objectives Upon completion of this activity, participants should be better able to: Explain the mechanism of action and rationale for combination therapy with PARP inhibitors and AR targeted therapies in the treatment of mCRPC |
Expiration |
Aug 12, 2023 |
Discipline(s) |
Physician CME |
Format |
Online |
Credits / Hours |
0.75 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty Neeraj Agarwal, MD Emmanuel S. Antonarakis, MD |
Sponsors / Supporters / Grant Providers |
Pfizer Inc. |
Keywords / Search Terms |
Relias LLC Relias LLC., FreeCME., Prostate Cancer Free CE CME |